$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
[Report Updated: 01-07-2017]

Published by Delve Insight: 01 Jul 2017 | 116528 | In Stock
Related Topics: Renal Cell Carcinoma

Introduction

DelveInsight’s, Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017” report provides comprehensive insights about marketed and Phase III products for the Metastatic Renal Cell Carcinoma (mRCC). The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Metastatic Renal Cell Carcinoma (mRCC) which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary information and data has been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and available databases.

Scope

• A review of the marketed products for Metastatic Renal Cell Carcinoma (mRCC) including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2020 and API manufacturer details.

• Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details

• API manufacturers for the marketed products with location details

• Emerging Phase III product profiles for Metastatic Renal Cell Carcinoma (mRCC) including product description, developmental activities, licensors & collaborators and chemical information

Reasons to Buy

• API intelligence for marketed drugs for the indication and gaining insights of API manufacturers

• Evaluate the marketing status and patent details of products to exploit opportunities for generic drug development

• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to the indication

• Establish a comprehensive understanding of the emerging Phase III products which can be future competitors in this space

Table of Contents
for Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 01-07-2017]

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

116528 | DIIT0070

Number of Pages

60

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016SummaryGlobalData's...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
13 Jul 2014 by FirstWord Pharma USD $695 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 01-07-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...